BICO company Biosero signs agreement to develop laboratory automation solutions to a value of 28 MUSD

Published: 8-Dec-2023
Research & Development

Biosero, a BICO company and developer of laboratory automation solutions to orchestrate scientific discoveries, has signed an agreement with a global life science company for a total value of 28 MUSD to design and build an automated R&D, hardware and software platform which consists of 5 sub-projects

The project is estimated to run from late Q4 2023 until Q1 2026 and the platform is aimed to shorten time for drug development workflows. The project will run in a ramp-up phase during 2024 and the vast majority of the project will be carried out and invoiced during 2025.
 
“This agreement is a milestone for the Group and it’s our largest project to date. It also shows the strength in Biosero’s offering for laboratory automation solutions and we expect to shorten current timelines for drug development through automation”, says Maria Forss, President and CEO, BICO.

See more

You may also like

Research & Development

Immunology CRO reports shift to autoimmunity projects

Read more
RoukenBio reports a sharp rise in autoimmunity drug development projects and an almost 50% decrease in immuno-oncology (I-O) studies, showcasing the shift in drug development trends

Trending Articles

  1. Sheffield University’s Energy Innovation Centre advances sustainable aviation Precision Anton Paar instruments support cutting-edge SAF research
  2. Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026
  3. Piramal Pharma Solutions awards Riverview and Digwal for patient centricity Two sites recognised for innovative initiatives that put patients first
  4. Pharma Partnering US Summit 20225 is all set to commence in Boston on 13–14 November 2025 This high-impact conference brings together top executives from pharma, biotech, investment firms, and advisory groups for two dynamic days of deal-making, networking, and thought leadership
  5. Abzena advances immunogenicity risk assessment in biologic drug development New white paper explores how early testing helps predict and prevent unwanted immune responses in therapeutic proteins

You may also like

Research & Development

Immunology CRO reports shift to autoimmunity projects

RoukenBio reports a sharp rise in autoimmunity drug development projects and an almost 50% decrease in immuno-oncology (I-O) studies, showcasing the shift in drug development trends
Research & Development

Merck partners with Promega to advance 3D cell drug discovery technologies

Partnership combines Merck’s chemistry and organoid expertise with Promega’s assay technologies
Manufacturing

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
Regulatory

TurboFil offers industry-leading glove testing systems

Partnership with RAVONA delivers precision and compliance in aseptic environments
Manufacturing

How to optimise your quality culture and maturity for success

NSF outlines how aligning culture, leadership and systems can strengthen compliance and performance
Regulatory

Shimadzu launches ALTRACE energy dispersive X-ray fluorescence spectrometer

High-sensitivity analysis and automated measurements for food, environmental, and pharmaceutical inspections
Manufacturing

Accelerating self-administration and homecare with large-volume prefillable glass syringe

SCHOTT Pharma launches 5.5 ml syringe compatible with autoinjectors to enable comfortable home injections
Subscribe now